Could Rituximab Be the Key to Managing Epidermolysis Bullosa Acquisita?
Epidermolysis bullosa acquisita (EBA) is a rare and often debilitating autoimmune blistering disease that remains notoriously difficult to manage. While treatments typically rely on a patchwork of anti-inflammatory and immunosuppressive therapies, results are often inconsistent—and relapses common.
This systematic review dives into the use of rituximab (RTX) as both monotherapy and in combination with other agents to assess its potential in treating EBA. The findings suggest promising outcomes, but with current data limited to case reports and chart reviews, how confident can we be in RTX’s role in EBA care?
J Drugs Dermatol. 2025;24(4):387–393. doi:10.36849/JDD.8483
